Selective imidazoline receptor agonists for metabolic syndrome.

Looks at abnormalities closely related to reduced insulin-mediated glucose disposal which constitutes the principal components of metabolic syndrome. The cause of the syndrome remaining obscure; The obesity studies that support the theory; The importance of antihypertensive agents; The selective imidazoline-I-receptor agonists that offer a innovative therapeutic approach to the treatment of hypertension.